Table 5.
Prognosis and treatment of patients with lung cancer after HTX.
| Parameter | Lung Cancer after HTX (n = 41) |
|---|---|
| Prognosis | |
| Curative care, n (%) | 13 (31.7%) |
| Palliative care, n (%) | 28 (68.3%) |
| Treatment | |
| Neoadjuvant chemotherapy, n (%) | 3 (7.3%) |
| Neoadjuvant radiotherapy, n (%) | 3 (7.3%) |
| Surgery, n (%) | 16 (39.0%) |
| Adjuvant chemotherapy, n (%) | 5 (12.2%) |
| Adjuvant radiotherapy, n (%) | 5 (12.2%) |
| Palliative chemotherapy, n (%) | 20 (48.8%) |
| Palliative radiotherapy, n (%) | 25 (61.0%) |
| Change of immunosuppressive drug therapy | |
| Switch from cyclosporin A to everolimus in combination with an antimetabolite, n (%) | 12 (29.3%) |
| Switch from cyclosporin A to sirolimus in combination with an antimetabolite, n (%) | 3 (7.3%) |
| Switch from tacrolimus to everolimus in combination with an antimetabolite, n (%) | 7 (17.1%) |
| Switch from tacrolimus to sirolimus in combination with an antimetabolite, n (%) | 0 (0.0%) |
| Switch to everolimus monotherapy with steroids, n (%) | 1 (2.4%) |
| Switch to sirolimus monotherapy with steroids, n (%) | 1 (2.4%) |
Abbreviations: HTX = heart transplantation; n = number.